AstraZeneca's Fasenra is the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing, the company said.
Pharmacy consultant and industry expert Bruce Kneeland takes a look at an independent PBM business model focused on saving money and improving patient outcomes.